Loading
A phase 2 trial of Selpercatinib in thyroid cancer, run by Eli Lilly and Company, active and no longer recruiting.
A Study of Selpercatinib (LY3527723) in Participants With Advanced Solid Tumors Including RET Fusion-positive Solid Tumors, Medullary Thyroid Cancer and Other Tumors With RET Activation is a phase 2 interventional study registered as NCT04280081 by Eli Lilly and Company, with 77 participants enrolled, started 2020-03-16 and due to reach its primary completion in 2021-03-25. Interventions recorded: Selpercatinib. Conditions listed: Solid Tumor, Medullary Thyroid Cancer. Results were posted on ClinicalTrials.gov in 2022; the figures recorded here are the registry's, not a publication's.
Numbers are from the trial as recorded here; see the source links in the table below. This is orientation, not medical advice: ask your team how closely the trial population matches you.
77 enrolled.
95% CI 48.2 to 85.7; Figures from the ClinicalTrials.gov results section (first posted 2022-06-02), not from a publication · 95% CI 2.5 to 100.0 · 95% CI 36.9 to 76.6
Source95% CI 50.7 to 79.1; Figures from the ClinicalTrials.gov results section (first posted 2022-06-02), not from a publication · 95% CI 2.5 to 100.0 · 95% CI 38.9 to 76.5
Source| Endpoint | Arm | n | Value | HR (95% CI) | p | Source |
|---|---|---|---|---|---|---|
| Primary Analysis Set: Overall Response Rate (ORR): Percentage of Participants With Complete Response (CR) or Partial Response (PR) as Assessed by Independent Review Committee (IRC), Overall Response (CR/PR)primary | RET Fusion Positive Non-small Cell Lung Cancer (NSCLC) Cohort 1 | 26 | 69.2% | - | - | link |
| RET Fusion Positive Thyroid Cancer (TC) Cohort 1 | 1 | 100% | ||||
| RET Mutant Medullary Thyroid Cancer (MTC) Cohort 2 | 26 | 57.7% | ||||
| Enrolled Population: Overall Response Rate (ORR): Percentage of Participants With Complete Response (CR) or Partial Response (PR) as Assessed by IRC, Overall Response (CR/PR)primary | Non-small Cell Lung Cancer (All NSCLC) | 47 | 66% | - | - | link |
| Thyroid Cancer (All TC) | 1 | 100% | ||||
| Medullary Thyroid Cancer (All MTC) | 29 | 58.6% |
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Selpercatinib, Eli Lilly (incl. Loxo), Thyroid cancer, Small-molecule kinase inhibitors.
Shares Medullary thyroid cancer, Thyroid cancer.
Shares Selpercatinib, Thyroid cancer, Small-molecule kinase inhibitors.
Shares Medullary thyroid cancer, Selpercatinib, Eli Lilly (incl. Loxo), Thyroid cancer.
Shares Selpercatinib, Eli Lilly (incl. Loxo), Small-molecule kinase inhibitors.
Shares Medullary thyroid cancer, Thyroid cancer.
Shares Medullary thyroid cancer, Selpercatinib.
Shares Medullary thyroid cancer, Thyroid cancer.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/